Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.75 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | PI4KA | P42356 | 4/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780339 | 0.92 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2CYP3A4PI4KA | |
| SCHEMBL27586243 | 0.86 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2CYP3A4PI4KA | |
| SCHEMBL7130526 | 0.86 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2CYP3A4PI4KA | |
| SCHEMBL21186241 | 0.81 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2CYP3A4PI4KA | |
| SCHEMBL9375983 | 0.81 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2CYP3A4PI4KA | |
| SCHEMBL2918453 | 0.80 | ALDH1A1 (0.72) | RAB9ANPC1SMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL3113690 | 0.80 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2CYP3A4PI4KA | |
| SCHEMBL7285327 | 0.79 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2CYP3A4PI4KA | |
| SCHEMBL785395 | 0.78 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2CYP3A4PI4KA | |
| SCHEMBL1913552 | 0.78 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2CYP3A4PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INST NAT SANTE RECH MED (FR) | 2025-12-18 | — | — | US | disclosed |
| EP-3565586-B1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4460500-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2024-11-13 | — | — | EP | disclosed |
| CN-118660885-A | Norbornene analogs and their use as potentiators of antitubercular drugs | 国家医疗保健研究所 | 2024-09-17 | — | — | CN | disclosed |
| WO-2023131649-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131649-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-13 | — | — | WO | disclosed |
| US-20230210966-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | LION BIOTECHNOLOGIES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210966-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | LION BIOTECHNOLOGIES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210966-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | LION BIOTECHNOLOGIES, INC. | 2023-07-06 | — | — | US | disclosed |
| CN-1422262-A | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors | ABBOTT GMBH & CO KG (DE) | 2003-06-04 | — | — | CN | disclosed |
| EP-1254123-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Abbott GmbH & Co. KG (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001057008-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) | 2001-08-09 | — | — | WO | disclosed |
| CN-1021047-C | 1,5-BENZOTHIAZEPINE DERIVATIVE AND PREPARATION THEREOF | SANKYO CO (JP) | 1993-06-02 | — | — | CN | disclosed |
| EP-0353032-B1 | 1,5-BENZOTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | Sankyo Company Limited (JP) | 1992-02-26 | — | — | EP | disclosed |
| US-5002942-A | Calcium channel blockers for cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1991-03-26 | — | — | US | disclosed |
| CN-1040195-A | 1,5-benzo thiophene azepine derivative and its preparation method and their application in the treatment cardiovascular disorder | SANKYO CO (JP) | 1990-03-07 | — | — | CN | disclosed |
| EP-0353032-A1 | 1,5-benzothiazepine derivatives, their preparation and their use in the treatment of cardiovascular disorders | Sankyo Company Limited (JP) | 1990-01-31 | — | — | EP | disclosed |
| US-4051084-A | BENZOTHIAZOLE | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-27 | — | — | US | disclosed |
| US-4039526-A | PRINTING, POLYACRYLONITRILE, POLYESTERS, POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210966-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | KCNN3, KCNK3, KCNA3 | RAB9A 3724/4885NPC1 1119/4885SMN1; SMN2 4083/4885 |
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | PBK, IL2, KCNN3 | RAB9A 4594/4885NPC1 1565/4885SMN1; SMN2 3141/4885 |
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | BBOX1, NDUFB6, NDUFB5 | RAB9A 2727/4885NPC1 3115/4885SMN1; SMN2 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.